JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Aktis Oncology (NASDAQ:AKTS) Stock

Aktis Oncology (NASDAQ:AKTS) had its price target upped by equities researchers at JPMorgan Chase & Co. from $30.00 to $33.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the technology company’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 25.93% from the stock’s previous close.

Other analysts have also recently issued research reports about the company. Raymond James Financial began coverage on Aktis Oncology in a research note on Monday, June 15th. They set a “strong-buy” rating and a $40.00 price objective on the stock. Weiss Ratings upgraded Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. HC Wainwright raised their price objective on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Finally, William Blair initiated coverage on shares of Aktis Oncology in a report on Wednesday, April 29th. They issued an “outperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.60.

Aktis Oncology Trading Up 2.4%

Shares of AKTS traded up $0.62 during midday trading on Tuesday, hitting $26.20. The company had a trading volume of 62,544 shares, compared to its average volume of 347,510. The stock has a market cap of $1.40 billion and a PE ratio of -69.58. The firm has a 50 day moving average price of $22.89. Aktis Oncology has a 52 week low of $14.72 and a 52 week high of $34.19.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The firm had revenue of $1.87 million for the quarter. On average, research analysts predict that Aktis Oncology will post -1.62 EPS for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.